Vaxcyte Inc

NASDAQ: pcvx
$89.78
+$3.27 (+3.8%)
Real Time Data Delayed 15 Min.

pcvx Stock Chart and Intraday Price

pcvx Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 353 HATCH DR, FOSTER CITY, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 7,773.94M USD
Shares Outstanding 108,408,000
Vaxcyte Inc, originally known as SutroVax, is a pioneering biotech firm focused on developing innovative protein vaccines aimed at combating bacterial infectious diseases. At the forefront of its pipeline is VAX-24, a promising vaccine candidate designed to prevent invasive pneumococcal disease. The company is also working on vaccines like VAX-31, VAX-A1, VAX-PG, and VAX-GI, targeting various bacterial pathogens and conditions, including antibiotic resistance and periodontitis. Founded in 2013 and based in San Carlos, California, Vaxcyte is committed to advancing vaccine science to protect global health.

pcvx Articles

Prediction: This Pharma Stock Will Be the Best Performer in 2025
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Trey Thoelcke
Published:

7+ Companies That Had Their IPO in 2020: Best and Worst Performers
2020 will forever be remembered as the year the coronavirus pandemic broke out. But in the year of the lockdowns, there were also 480 initial public offerings on the U.S. stock market — a record...
Melly Alazraki
Published:
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.